Quick answers

What is NAD+ and what is it used for in research?
NAD+ is classified within the Longevity & Cellular group. Coenzyme NAD+ delivered subcutaneously or via slow IV; substrate for sirtuins, PARP, and CD38. Investigated for mitochondrial function, metabolic resilience, and DNA-repair pathways. Research applications focus on the pathways outlined below. All references on this page describe published research only, NAD+ is supplied for in-vitro and laboratory use, not for human consumption.
How does NAD+ work?
Primary mechanism: Nicotinamide adenine dinucleotide; replenishes cellular NAD+ pools for mitochondrial bioenergetics and sirtuin signaling. Downstream effects depend on dose, timing, and the biological system under investigation. Receptor binding and post-receptor signalling for NAD+ remain areas of active study, and several proposed effects are supported only by preclinical data.
What is the typical NAD+ research dose?
Published research protocols for NAD+ describe per-dose ranges of 100–500 mg / day, with a weekly total near 0.7–3.5 g, administered daily or prn sc/iv. Typical cycle: 4–12 week pulses. These ranges reflect the literature and are not dosing recommendations for any individual.
Where can I buy NAD+ in Thailand?
NAD+ is supplied by Thailand Peptides, a Bangkok-based research-peptide supplier. Orders are placed directly via WhatsApp to the Bangkok research desk, no cart, no account, no forms. Pricing and shipping are provided on request. Open a line with the research desk →
How fast can NAD+ be delivered in Thailand?
Same-week delivery across Thailand is standard for orders confirmed within business hours (GMT+7, Monday–Saturday). Bangkok metro deliveries typically arrive within 1–3 business days; other provinces within 3–5. Regional Southeast Asia shipping is available on request.

What is NAD+?

NAD+ is a research peptide in the Longevity & Cellular class. Nicotinamide adenine dinucleotide; replenishes cellular NAD+ pools for mitochondrial bioenergetics and sirtuin signaling. It is studied at per-dose ranges of 100–500 mg / day (0.7–3.5 g weekly), administered daily or prn sc/iv over cycles of 4–12 week pulses. Supplied in Thailand by Thailand Peptides, Bangkok-based, research use only.

Coenzyme NAD+ delivered subcutaneously or via slow IV; substrate for sirtuins, PARP, and CD38. Investigated for mitochondrial function, metabolic resilience, and DNA-repair pathways.

Published and preclinical data are summarised below; dose ranges shown reflect protocols in the research literature and should be interpreted accordingly.

How does NAD+ work?

Primary mechanism: Nicotinamide adenine dinucleotide; replenishes cellular NAD+ pools for mitochondrial bioenergetics and sirtuin signaling. Research on NAD+ implicates downstream effects on related signalling cascades, with magnitude and clinical relevance dependent on dose, timing, and individual pharmacogenomic factors.

Receptor binding affinity and post-receptor signalling for NAD+ remain areas of active investigation; several proposed effects within the Longevity & Cellular class are currently supported only by in-vitro or rodent data, and should be interpreted accordingly.

NAD+ dosage & protocol

Reference protocol for NAD+ (research context only, drawn from published literature):

  • Per dose: 100–500 mg / day
  • Weekly total: 0.7–3.5 g
  • Frequency: Daily or PRN SC/IV
  • Cycle: 4–12 week pulses
Order NAD+
Ready to order? WhatsApp the Bangkok research desk, pricing and availability confirmed within the chat.
Ask about NAD+ ≥98% HPLC purity · supplier COA on file · Bangkok-based

Stacking NAD+

Commonly referenced pairing with NAD+: 5-Amino-1MQ, MOTS-c. Stacking rationale should be grounded in complementary mechanisms, not additive speculation; interactions at shared receptors or enzymatic pathways should be accounted for. Both compounds in a NAD+ stack are supplied by Thailand Peptides on the same order via the Bangkok research desk.

Contraindications

Active malignancy, severe hepatic impairment. Additional caution is warranted in individuals with hepatic or renal impairment, endocrine disorders, or concurrent pharmacotherapy affecting the pathways described above.

Citations

  1. Yoshino J, et al. NAD+ Intermediates: The Biology and Therapeutic Potential of NMN and NR. Cell Metab. 2018. PMID: 29249689
  2. Trammell SAJ, et al. Nicotinamide riboside is uniquely and orally bioavailable in mice and humans. Nat Commun. 2016. PMID: 27721479
  3. Martens CR, et al. Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults. Nat Commun. 2018. PMID: 29599478

References curated from PubMed. Additional literature summarised in the Thailand Peptides research library.